| Name | Title | Contact Details |
|---|
Ohio Bureau Of Workers' Compensation is a Independence, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
French Family-owned URGO Group is an international leading company and world expert in advanced wound care and selfcare. With its two divisions Urgo Medical and Urgo Consumer Healthcare, URGO Group is engaged on day to day basis with patients, healthcare professionals and the general public. The Group develops innovative wound dressings that have proven their medical superiority through clinical studies, to address an increased need worldwide for the care of chronic wounds. It gives access to responsible healthcare solutions in the areas of first aid, nutritional supplements, sexual well-being, cold and allergies. 3 300 collaborators participate in these missions in 22 countries, among which 10 industrial sites serve the needs of our clients.
The mission of Cascadia Behavioral Healthcare is to create hope and opportunity for low income people with mental illnesses and addictions, blending innovation and determination with competence, inclusion and compassion. The heart of Cascadia is our people those we serve, our co-workers, and our community partners. Together we are focused on efficiency, committed to diversity and grounded in compassion.We are consumers, counselors, accountants, case managers, nurses, administrative support workers, doctors, and the full complement of all the people needed to bring results. For many of us this is not just a job, it`s a calling. Our Vision: We envision a future where everyone with a mental illness or addiction will recover and have a full life in the community. Our Mission: Cascadia provides healing, homes, and hope for people living with mental health and addiction challenges. Cascadia brings health and housing services to those who need them most. With 75 sites in Oregon`s Multnomah and Clackamas Counties, we help create a sense of community We`ve learned that families are an important part of people`s lives and offer services unique to children, families, adults and older adults: •Community- and Clinic-Based Mental Health and Addiction Services •Peer Wellness •Urgent and Emergency Services •Homeless Services •Forensics •Medical •Housing Development
At Clinipace, a global, full-service contract research organization (CRO), our approach to clinical research is personal. We deliver a level of collaboration and flexibility not possible in a traditional CRO environment. Our personalized services and solutions, local regulatory expertise and therapeutic leadership are designed to face the most difficult industry challenges across all major therapeutic areas including oncology, gastroenterology, nephrology and urology. We strive to improve the way clinical research is performed and impact the future of health care using the most advanced technology and a CHALLENGE ACCEPTED approach. In April 2021, Clinipace & dMed merged creating a differentiated mid-size CRO with the largest Asia-Pacific presence. We are proud to have such a strong group of global investors focused on improving healthcare outcomes and giving sponsors a better CRO choice. dMed`s 2019 acquisition of Target Health commenced the process of building a Next Generation global CRO for biotech and pharmaceutical companies. Our investors have invested over $230M to build the next great global CRO. dMed`s acquisition of Target Health in 2019 began dMed`s evolution from a local to global CRO. Target Health LLC is owned by dMedClinical Co. Ltd., a privately held company that is majority owned, operated, managed, and controlled by a U.S. citizen and foreign entities located in the People`s Republic of China. Dr. Lingshi Tan, is the aforementioned U.S. citizen currently residing in Shanghai, China. Dr. Tan moved to Shanghai (from New York) to become Pfizer`s VP of Worldwide Development Operations, and Chairman and General Manager of Pfizer (China) Research & Development Co. Dr. Tan founded dMed in 2016 to satisfy the local demand for a high quality, responsive, flexible CRO.
Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is transforming the science of combination therapy and developing products to improve outcomes for patients with cancer. The Company is working to establish a new treatment paradigm in which rationally-designed, fully-integrated combination products replace combination regimens of individual agents. Celator`s proprietary technology platform, CombiPlex®, identifies the most effective synergistic ratio of the component drugs, optimizes the pharmacology of the drug combination prior to human clinical trials, allows simultaneous administration of the components as a single product and maintains the synergistic ratio of the components after administration thereby exposing tumor cells to the right amounts of drug for the right length of time.